Lenvatinib inhibits the growth of gastric cancer patient-derived xenografts generated from a heterogeneous population.

ABSTRACT:

Background

Lenvatinib is a multitargeted tyrosine kinase inhibitor that is being tested in combination with immune checkpoint inhibitors to treat advanced gastric cancer; however, little data exists regarding the efficacy of lenvatinib monotherapy. Patient-derived xenografts (PDX) are established by engrafting human tumors into immunodeficient mice. The generation of PDXs may be hampered by growth of lymphomas. In this study, we compared the use of mice with different degrees of immunodeficiency to establish PDXs from a diverse cohort of Western gastric cancer patients. We then tested the efficacy of lenvatinib in this system.

Methods

PDXs were established by implanting gastric cancer tissue into NOD.Cg-Prkdc^scidIl2rg^tm1Wjl/SzJ (NSG) or Foxn1^nu

SUBMITTER: Karalis JD 

PROVIDER: S-EPMC8900296 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature